Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. [ 2 ] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors ...
Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment. The ...
Regeneron said "it was the first time" a CRL for this reason was issued by the U.S. Food and Drug Administration, which has been lately working to raise the bar for cancer drug developers seeking ...
Regeneron will also get a tax break on about $50 million of the renovation costs at the site, with exemptions of up to about $4.19 million in state and local sales taxes, according to IDA documents.
On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. [26] [27] The drug was provided by the company in response to a "compassionate use" (temporary authorization for use) request from the president's physicians. [26]
Regeneron's shares closed down 8.6% at $715.9. The U.S. Food and Drug Administration issued a complete response letter, indicating the agency has review US FDA declines to approve Regeneron's ...
In 2014, Yancopoulos led the launch of the Regeneron Genetics Center, a major initiative in human genetic research that has sequenced exomes from over 1,000,000 people as of February 2020. [23] [24] Forbes magazine states Yancopoulos' financial stake in Regeneron has made him a billionaire. He is the first research and development chief in the ...
Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR ...